Focus On Asia
Takeda, Astellas, Daiichi Sankyo, Chugai, Shionogi all revised their annual forecasts upwards due to forex rate impact and saw mostly solid overseas sales growth in the fiscal first half.
Ex-Janssen India chief and BSV CEO Sanjiv Navangul shares with Scrip glimpses of his life and professional journey including chasing the IAS dream early on, the heady days at Hoechst with a stint in Moscow, challenges around Sirturo’s debut and unprecedented preps that fueled Januvia’s big run during his innings at MSD.
Novo Nordisk India MD talks to Scrip about what to expect when Wegovy arrives in India and the local trajectory of Rybelsus. The Danish group also shared findings of a study around obesity.
Low prices and intense competition for innovative drugs at home continue to drive Chinese biotechs' globalization. Broader domestic commercial health insurance might provide the key to change.
LaNova Medicines, as well as other Chinese RNA interference specialists and developers of stem cell-based therapies, were among those securing new funds from venture capital and private equity firms over the past few months.
Oscotec co-CEO Taeyoung Yoon highlights anti-resistance and anti-tau therapies as the Korean bioventure’s next possible blockbuster candidates after the landmark US approval of lazertinib for lung cancer.
The exact causes leading to Chinese authorities’ investigation of the UK major remain unclear at this point, but its key oncology drugs are facing fierce local competition from homegrown rivals.
Continued growth for mainstay Entyvio and cancer newcomer Fruzaqla drove growth at Takeda in the fiscal first half, with the Japanese major brightening its outlook for the full year.
Lanreotide supply challenges could impact Cipla’s US revenues in the coming quarter, while the firm hopes it can seize emerging opportunities in the GLP-I segment in India, where Novo Nordisk and Eli Lilly are progressing filings for their blockbuster products.
High patient needs, a large healthcare market and innovation potential in the biotech sector in China still appear to be maintaining and attracting investments by overseas biopharma companies, including by Bayer and Lilly in biotech start-ups and Lilly in manufacturing.
Strides is to supply semaglutide and liraglutide to generics companies amid global capacity constraints and drug shortages, ahead of loss of exclusivity. An ability to make drug-device combinations has meant it has contracts for seven of the eight GLP-1 agonists, and counting
Following strong demand for offerings by D&D Pharmatech and ENCell, sentiment around biopharma IPOs in Korea appears to be improving, with several other ventures planning to float.
ZL-1310, a DLL3-targeting ADC, has shown a 74% objective response rate in extensive-stage small cell lung cancer after platinum-based chemotherapy, making it a new contender in this setting.
Biostar plans to raise up to $41m through a Hong Kong IPO, which help the Chinese chemotherapy specialist progress lead asset utidelone for various oncology indications.
Multiple Japanese ventures presented updates on their novel pipeline assets and modalities at BioJapan, including cell and gene therapies and combination treatments, despite lingering financing challenges.
CEO of Sumitomo Pharma America unit, Adele M. Gulfo, draws from experiences working across companies including Pfizer, to advise on go-to-market strategies for a portfolio across primary care to rare disease.
Excellence, innovation, deal-making and personal achievement across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2024, held in Tokyo on 22 October.
Sanofi’s EVP (general medicines), Olivier Charmeil, talks about pharma’s evolving go-to-market strategies that enmesh a more personalized, data-driven approach, why the medical, legal, and regulatory (MLR) review process needs to be faster and also impressive learnings from Amazon, Netflix and Ikea around building customer experience.
In a video interview, Nandini Piramal, chairperson of Piramal Pharma, speaks with Scrip about a focus on on-patent products, an integrated ADC offering, a measured approach to the proposed BIOSECURE Act and the company’s strategy to double revenue to about $2bn
While oncology and discovery-stage assets accounted for the majority of R&D projects supported by a Korean state fund this year, new modalities such as ADCs and TPDs are emerging.